Novel Study Designs for New HIV Prevention Products
A presentation by Deborah Donnell, of the Fred Hutchinson Cancer Research Center University of Washington, discussing trial design when PrEP is available. How can the field justify randomization to an experimental drug when we have something known to work? If we give study participants PrEP, how can we know a new experimental drug is working?
- Topics:
- Centering Communities
Was this content helpful?
Tell us how we can improve the content.
Was this content helpful?
Thank you for your feedback!